Other

Baylor College of Medicine

Aerojet Fine Chemicals LLC

Splice Machine, Inc.

Texas Heart Institute

Ampac Fine Chemicals LLC

Apple Inc.

John M Leach

James F Martin

Aslam A Malik

Thomas G Archibald

Roland P Carlson

Hasan Palandoken

Joy A Stringer

Robert G Miotke

Todd Ryan Heallen

Yuka Morikawa

Monte Zweben

Scott Fines

Gene Davis

Tanner Monroe

Antoine R Raux

Daniel Gomez Ferro

The present disclosure encompasses methods for generating cells or tissue from existing cells with one or more mutated variants of Yap. In specific embodiments, the disclosure regards treatment of existing cardiomyocytes with one or more mutated variants of Yap that causes them to divide and generate new cardiomyocytes. In specific cases, the mutated variant of Yap has serine-to-alanine substitutions at 1, 2, 3, 4, 5, 6, or more serines of Yap.

Dominant active yap, a hippo effector, induces chromatin accessibility and cardiomyocyte renewal

Embodiments of the disclosure include methods and compositions for the renewal of cardiomyocytes by targeting the Hippo pathway. In particular embodiments, an individual with a need for cardiomyocyte renewal is provided an effective amount of a shRNA molecule that targets the Sav1 gene. Particular shRNA sequences are disclosed.

Hippo and dystrophin complex signaling in cardiomyocyte renewal

An example process includes: receiving a natural language input having a start time and including first and second portions respectively received from the start time to a first time and from the start time to a second time after the first time; determining an end time of the natural language input; executing, at least partially between the first time and the end time, a first task flow based on the first portion, including: obtaining a first executable object representing a first candidate action; executing, at least partially between the second time and the end time, a second task flow based on the second portion, including: obtaining a second executable object representing a second candidate action; in response to determining the end time, selecting a candidate action from a plurality of candidate actions each represented by a respective executable object; and executing the respective executable object representing the selected candidate action.

Speculative task flow execution

Embodiments of the disclosure include methods and compositions related to treating or reducing the severity or delaying the onset of one or more cardiac conditions in a mammal. In particular embodiments, the compositions concern Park2 and its use for a cardiac medical condition. In specific cases, effective amounts of Park2 polynucleotide(s) and/or Park2 polypeptide(s) are provided to an individual in need thereof, including for heart failure, for example. The administration may be locally to the heart, for example.

Hippo pathway deficiency reverses systolic heart failure post-infarction

A system for executing a plurality of transactions comprises a first processor and a memory. The first processor is configured to execute a first transaction comprising: providing a plurality of indications to make a plurality of first changes to a plurality of first records of a database; and committing the first transaction by updating the status of the first transaction in a transaction table while not providing an indication to update the status of the first records from pending. The memory is coupled to the first processor and configured to store the transaction table.

Transaction execution commitment without updating of data row transaction status

A system for analysis and transaction processing includes an interface and a processor. The interface is configured to receive a task. The processor is configured to determine a processing estimate associated with the task by determining required resources for a set of possible processing solutions to perform the task and to determine a task engine based at least in part on the processing estimate. The task engine comprises an analysis engine or a transaction engine. The analysis engine or the transaction engine is used to process the task. The processor is further to provide the task to the task engine.

Splitting transaction and analysis queries

The present invention is directed to methods and compositions that provide therapy for at least one medical condition that directly or indirectly affects cardiac muscle cells (also known as cardiomyocytes) in a mammalian individual, including humans, dogs, cats, horse pigs, and so forth. The medical condition may be of any kind, including a cardiac condition such as heart failure, cardiomyopathy, myocardial infarction, and so forth. The medical condition may have a cardiac condition as its primary symptom or cause or it may be a secondary symptom or cause. The individual may be male or female and may be of any age.

The present invention provides a new process for the preparation of 2R,3S-N-isobutyl-N-(2-hydroxy-3-amino-4-phenylbutyl)-p-nitrobenzenesulfonylamide hydrochloride, wherein this compound is prepared directly from the chloromethylalcohol. Importantly, the process of the present invention results in higher yields of 2R,3S-N-isobutyl-N-(2-hydroxy-3-amino-4-phenylbutyl)-p-nitrobenzenesulfonylamide hydrochloride without sacrificing its purity. The processes of the present invention can be used to prepare not only the 2R,3S-derivative, but also the 2S,3S-, 2S,2R- and the 2R,3R-derivatives.

[object Object]

The present invention provides a new process for the preparation of 2R,3S-N-isobutyl-N-(2-hydroxy-3-amino-4-phenylbuty1)-p-nitrobenzenesulfonylamide hydrochloride, wherein this compound is prepared directly from the chloromethylalcohol. Importantly, the process of the present invention results in higher yields of 2R,3S-N-isobutyl-N-(2-hydroxy-3-amino-4-phenylbutyl)-p-nitrobenzenesulfonylamide hydrochloride without sacrificing its purity. The processes of the present invention can be used to prepare not only the 2R,3S-derivative, but also the 2S,3S-, 2S,2R- and the 2R,3R-derivatives.

Preparation of 2R,3S-N-isobutyl-N-(2-hydroxy-3-amino-4-phenylbutyl)-P-nitrobenzenesulfonylamide hydrochloride and other derivatives of 2-hydroxy-1,3-diamines

The present invention provides a new process for the preparation of 2S,3S-N-isobutyl-N-(2-hydroxy-3-amino-4-phenylbutyl)-p-nitrobenzenesulfonylamide hydrochloride, wherein this compound is prepared directly from the chloromethylalcohol. Importantly, the process of the present invention results in higher yields of 2S,3S-N-isobutyl-N-(2-hydroxy-3-amino-4-phenylbutyl)-p-nitrobenzenesulfonylamide hydrochloride without sacrificing its purity. The processes of the present invention can be used to prepare not only the 2S,3S-derivative, but also the 2R,3S-, 2S,2R- and the 2R,3R-derivatives.

Preparation of 2S,3S-N-isobutyl-N-(2-hydroxy-3-amino-4-phenylbutyl)-P-nitrobenzenesulfonylamide hydrochloride and other derivatives of 2-hydroxy-1,3-diamines

Growing community of inventors

Port Jefferson, NY, United States of America

John M Leach